Search Results - "Rustgi, V.K."

13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION by Everson, G.T, Di Bisceglie, A.M, Vierling, J.M, Hsieh, F, Trenkle, J.D, Kanwar, B, Subramanian, M, McHutchison, J.G, Ghalib, R.H, Rustgi, V.K, Kwo, P.Y

Get full text

2001 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NITAZOXANIDE PLUS PEGINTERFERON AND RIBAVIRIN IN HCV GENOTYPE 1 NAIVE PATIENTS: WEEK 12 SUSTAINED VIROLOGIC RESPONSE RATE by Bacon, B.R, Shiffman, M.L, Lim, J.K, Berman, A, Rustgi, V.K, Keeffe, E.B

Get full text

1096 ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION by Bronowicki, J.-P, Pol, S, Thuluvath, P, Larrey, D, Martorell, C.T, Rustgi, V.K, Morris, D.W, Younes, Z, Fried, M.W, Bourliere, M, Hezode, C, Reddy, R, Massoud, O, Abrams, G.A, Ratziu, V, He, B, Eley, T, Ahmad, A, Thiry, A, Llamoso, C, Mendez, P, Hughes, E

Get full text

2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS by Lawitz, E, Rodriquez-Torres, M, Rustgi, V.K, Hassanein, T, Rahimy, M.H, Crowley, C.A, Freddo, J.L, Muir, A, McHutchison, J

Get full text

1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION by Bronowicki, J.-P, Pol, S, Thuluvath, P.J, Larrey, D, Martorell, C.T, Rustgi, V.K, Morris, D.W, Younes, Z, Fried, M.W, Bourliere, M, Hezode, C, Massoud, O, Abrams, G.A, Ratziu, V, Thiry, A, Llamoso, C, Hughes, E.A, Hindes, R.G

Get full text

1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS by Pol, S, Ghalib, R.H, Rustgi, V.K, Martorell, C, Everson, G.T, Tatum, H.A, Hezode, C, Lim, J.K, Bronowicki, J.-P, Abrams, G.A, Brau, N, Morris, D.W, Thuluvath, P, Reindollar, R, Yin, P.D, Diva, U, Hindes, R, McPhee, F, Gao, M, Thiry, A, Schnittman, S, Hughes, E.A

Get full text

778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS by Zeuzem, S, Nelson, D.R, Andreone, P, Ferenci, P, Herring, R, Jensen, D.M, Marcellin, P, Pockros, P, Rodriguez-Torres, M, Rossaro, L, Rustgi, V.K, Sepe, T, Sulkowski, M, Thomason, I.R, Yoshida, E, Chan, A, Hill, G

Get full text

EE508 Cost of Liver Cancer Screening in Patients with Cirrhosis by Samur, S., Rustgi, V.K., Parikh, N.D., Yang, J.D., Roberts, L.R., Nguyen, M.H., Ozbay, A.B., Ayer, T., Singal, A.G., Chhatwal, J.

Get full text

Impact of donor age on graft survival among liver transplant recipients: analysis of the United Network for Organ Sharing database by Rustgi, S.D, Marino, G, Halpern, M.T, Umana, W.O, Tolleris, C, Rustgi, V.K

Get full text

197NF-κB activation in liver allografts correlates with severity of histological disease & fibrosis in recurrent hepatitis C virus disease by Chejfec, G., Gaweco, A.S., Wiesner, R.H., Rustgi, V.K., Porayko, M., Yong, S., Harig, J., McClatchey, K.D., Van Thiel, D.H.

Get full text